Avandia Lawsuit Archives

July 6, 2012 by John

Avandia Lawsuit News

07/06/2012 Avandia Lawsuit New Cases: The Avandia Lawsuit was thought to be over by many looking for representation from qualified Avandia Lawsuit attorneys for cardiac incidents tied to the drug. Encouraging news for those whose family member died from a cardiac event or for those suffering from congestive heart failure after taking Avandia is that several qualified attorneys are still pursuing new Avandia Lawsuit cases. You can be connected with one of these interested and experienced attorneys by calling (800) 611-7080.

News of an Avandia Lawsuit first began after the adverse events related to cardiac issues became public information. The number of those affected by Avandia side effects has continued to grow during the 12-plus years Avandia has been available to the public.

The diabetic drug has caused quite a controversy for many years and for several different reasons. The FDA announced in 2010 that Avandia would be restricted to only patients who could not control their blood sugar through the use of other medications. Heart attack and congestive heart failure events are the primary reason for the former restrictions and for filing an Avandia Lawsuit. Avandia was also at the center of several counts in the recent $3 billion suit against the maker, GlaxoSmithKline. These counts allege that GSK failed to warn about the known reactions related to using Avandia, including heart complications.

The consumers of Avandia have filed Avandia Lawsuit cases over the course of two years for the heart problems and risks created by this drug. The recent update to Avandia Lawsuit news is that cases can still be pursued for a limited window of time. It is not in the best interest of potential plaintiffs in the Avandia Lawsuit to wait another day to begin filing. The Avandia Lawsuit is likely in the final months of able time to file a new case before the docket closes. Please contact Best Legal Source for access to a proven and dependable attorney active in the Avandia Lawsuit case: (800) 611-7080

Avandia Lawsuit Update

July 2, 2012 by admin

Avandia Lawsuit Update

(07/02/2012): Avandia Lawsuit: The British manufacturer, GalaxoSmithKline (GSK) will pay $3 billion to clear charges and allegations of marketing drugs for uses other than those approved by the U.S. Food and Drug Administration. This settlement is historic as the largest case of healthcare fraud in U.S. history.

GSK is the manufacturer of well-known drugs such as Avandia, Paxil and Wellbutrin.

An attorney involved in the case, Tavy Deming said that allegations by internal personnel were investigated and verified. “The company took no action, choosing hefty profits over compliance and patient safety,“ Deming said.

Among the charges of illegal marketing, there are mentions of the diabetes drug Avandia. GSK pled guilty to marketing Paxil and Wellbutrin for off-label uses and for failing to report clinical data on Avandia. Certain safety information including the potential risk of congestive heart failure and heart attack were not given to the prescribing doctors. Since this time, the FDA has forced GSK to add two black-box warnings to the Avandia label. If you or a loved one experienced heart damage while taking Avandia, you may be eligible to join the Avandia Lawsuit.

Promoting a drug for uses other than the approved on-label usage is considered “misbranding” in the United States and is not permitted. GSK plead guilty to these charges and will be held accountable. It is not too late to begin entering the Avandia Lawsuit to hold GSK accountable for the failure to warn of known adverse effects. Contact us at (800) 611-7080 to learn how you can be compensated for damages related to congestive heart failure through an Avandia Lawsuit.

The time to file an Avandia Lawsuit is close to ending. It is advisable to explore your legal options today and join serious discussions with an attorney regarding the Avandia Lawsuit action. Best Legal Source is a strong ally to have in this process. Please call today.